Literature DB >> 8410252

Thymidine kinase-mediated killing of rat brain tumors.

D Barba1, J Hardin, J Ray, F H Gage.   

Abstract

Gene therapy has many potential applications in central nervous system (CNS) disorders, including the selective killing of tumor cells in the brain. A rat brain tumor model was used to test the herpes simplex virus (HSV)-thymidine kinase (TK) gene for its ability to selectively kill C6 and 9L tumor cells in the brain following systemic administration of the nucleoside analog ganciclovir. The HSV-TK gene was introduced in vitro into tumor cells (C6-TK and 9L-TK), then these modified tumor cells were evaluated for their sensitivity to cell killing by ganciclovir. In a dose-response assay, both C6-TK and 9L-TK cells were 100 times more sensitive to killing by ganciclovir (median lethal dose: C6-TK, 0.1 microgram ganciclovir/ml; C6, 5.0 micrograms ganciclovir/ml) than unmodified wild-type tumor cells or cultured fibroblasts. In vivo studies confirmed the ability of intraperitoneal ganciclovir administration to kill established brain tumors in rats as quantified by both stereological assessment of brain tumor volumes and studies of animal survival over 90 days. Rats with brain tumors established by intracerebral injection of wild-type or HSV-TK modified tumor cells or by a combination of wild-type and HSV-TK-modified cells were studied with and without ganciclovir treatments. Stereological methods determined that ganciclovir treatment eliminated tumors composed of HSV-TK-modified cells while control tumors grew as expected (p < 0.001). In survival studies, all 10 rats with 9L-TK tumors treated with ganciclovir survived 90 days while all untreated rats died within 25 days. Curiously, tumors composed of combinations of 9L and 9L-TK cells could be eliminated by ganciclovir treatments even when only one-half of the tumor cells carried the HSV-TK gene. While not completely understood, this additional tumor cell killing appears to be both tumor selective and local in nature. It is concluded that HSV-TK gene therapy with ganciclovir treatment does selectively kill tumor cells in the brain and has many potential applications in CNS disorders, including the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410252     DOI: 10.3171/jns.1993.79.5.0729

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  18 in total

Review 1.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

Review 3.  Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy.

Authors:  M H Tuszynski; F H Gage
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

Review 4.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

5.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

Authors:  J Fick; F G Barker; P Dazin; E M Westphale; E C Beyer; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

6.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.

Authors:  D Barba; J Hardin; M Sadelain; F H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Ganciclovir mediated regression of rat brain tumors expressing the herpes simplex virus thymidine kinase imaged by magnetic resonance.

Authors:  A Maron; T Gustin; I Mottet; R Demeure; J N Octave
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 8.  Gene therapy for diseases of the nervous system.

Authors:  J Fick; M A Israel
Journal:  West J Med       Date:  1994-09

9.  Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.

Authors:  S J Tapscott; A D Miller; J M Olson; M S Berger; M Groudine; A M Spence
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

Review 10.  Gene therapy of neoplastic meningosis.

Authors:  F D Vrionis
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.